HAE
HealthcareHaemonetics Corporation
$82.11
+$2.13 (+2.66%)
Jan 5, 2026
Price History (1Y)
Analysis
Haemonetics Corporation is a healthcare company that operates in the medical devices industry. With a market capitalization of $3.96 billion and 3023 employees, it is a significant player in its sector. The company's financial health is characterized by moderate profitability, with gross margin standing at 59.5%, operating margin at 21.0%, and profit margin at 12.7%. Its returns on equity and assets are 19.5% and 6.4%, respectively. Haemonetics' balance sheet shows a debt-to-equity ratio of 144.28, indicating significant borrowing, while its cash position stands at $297.06 million. Haemonetics' valuation is reflected in its price-to-earnings (P/E) ratios, with a forward P/E of 15.01 and a trailing twelve-month P/E of 23.39. The company's revenue growth has been negative year-over-year (-5.3%), while earnings growth has been positive at 22.7%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $3.96B
- P/E Ratio
- 23.39
- 52-Week High
- $87.32
- 52-Week Low
- $47.32
- Avg Volume
- 846.12K
- Beta
- 0.29
Company Info
- Industry
- Medical Devices
- Exchange
- NYQ
- Country
- United States
- Employees
- 3,023